Search

Your search keyword '"Johnson, Rebecca I."' showing total 21 results
Start Over Author "Johnson, Rebecca I."
21 results on '"Johnson, Rebecca I."'

3. IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

Author

Nikitin, Pavel A., primary, DiMuzio, Jillian M., additional, Dowling, John P., additional, Patel, Nirja B., additional, Bingaman-Steele, Jamie L., additional, Heimbach, Baron C., additional, Henriquez, Noeleya, additional, Nicolescu, Chris, additional, Polley, Antonio, additional, Sikorski, Eden L., additional, Howanski, Raymond J., additional, Nath, Mitchell, additional, Shukla, Halley, additional, Scheaffer, Suzanne M., additional, Finn, James P., additional, Liang, Li-Fang, additional, Smith, Todd, additional, Storm, Nadia, additional, McKay, Lindsay G. A., additional, Johnson, Rebecca I., additional, Malsick, Lauren E., additional, Honko, Anna N., additional, Griffiths, Anthony, additional, Diamond, Michael S., additional, Sarma, Purnanand, additional, Geising, Dennis H., additional, Morin, Michael J., additional, and Robinson, Matthew K., additional

Published
2022
Full Text
View/download PDF

4. Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail

Author

Nikitin, Pavel A., primary, DiMuzio, Jillian M., additional, Dowling, John P., additional, Patel, Nirja B., additional, Bingaman-Steele, Jamie L., additional, Heimbach, Baron C., additional, Henriquez, Noeleya, additional, Nicolescu, Chris, additional, Polley, Antonio, additional, Howanski, Raymond J., additional, Nath, Mitchell, additional, Shukla, Halley, additional, Finn, James P., additional, Liang, Li-fang, additional, Smith, Todd, additional, Storm, Nadia, additional, McKay, Lindsay G. A., additional, Johnson, Rebecca I., additional, Malsick, Lauren E., additional, Honko, Anna N., additional, Griffiths, Anthony, additional, Sarma, Purnanand, additional, Geising, Dennis H., additional, Morin, Michael J., additional, and Robinson, Matthew K., additional

Published
2021
Full Text
View/download PDF

5. An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

Author

Zabaleta, Nerea, primary, Dai, Wenlong, additional, Bhatt, Urja, additional, Hérate, Cécile, additional, Maisonnasse, Pauline, additional, Chichester, Jessica A., additional, Sanmiguel, Julio, additional, Estelien, Reynette, additional, Michalson, Kristofer T., additional, Diop, Cheikh, additional, Maciorowski, Dawid, additional, Dereuddre-Bosquet, Nathalie, additional, Cavarelli, Mariangela, additional, Gallouët, Anne-Sophie, additional, Naninck, Thibaut, additional, Kahlaoui, Nidhal, additional, Lemaitre, Julien, additional, Qi, Wenbin, additional, Hudspeth, Elissa, additional, Cucalon, Allison, additional, Dyer, Cecilia D., additional, Pampena, M. Betina, additional, Knox, James J., additional, LaRocque, Regina C., additional, Charles, Richelle C., additional, Li, Dan, additional, Kim, Maya, additional, Sheridan, Abigail, additional, Storm, Nadia, additional, Johnson, Rebecca I., additional, Feldman, Jared, additional, Hauser, Blake M., additional, Contreras, Vanessa, additional, Marlin, Romain, additional, Tsong Fang, Raphaël Ho, additional, Chapon, Catherine, additional, van der Werf, Sylvie, additional, Zinn, Eric, additional, Ryan, Aisling, additional, Kobayashi, Dione T., additional, Chauhan, Ruchi, additional, McGlynn, Marion, additional, Ryan, Edward T., additional, Schmidt, Aaron G., additional, Price, Brian, additional, Honko, Anna, additional, Griffiths, Anthony, additional, Yaghmour, Sam, additional, Hodge, Robert, additional, Betts, Michael R., additional, Freeman, Mason W., additional, Wilson, James M., additional, Le Grand, Roger, additional, and Vandenberghe, Luk H., additional

Published
2021
Full Text
View/download PDF

10. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Author

Clark, Sarah A., primary, Clark, Lars E., additional, Pan, Junhua, additional, Coscia, Adrian, additional, McKay, Lindsay G.A., additional, Shankar, Sundaresh, additional, Johnson, Rebecca I., additional, Brusic, Vesna, additional, Choudhary, Manish C., additional, Regan, James, additional, Li, Jonathan Z., additional, Griffiths, Anthony, additional, and Abraham, Jonathan, additional

Published
2021
Full Text
View/download PDF

11. Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mouse and non-human primates

Author

Zabaleta, Nerea, primary, Dai, Wenlong, additional, Bhatt, Urja, additional, Chichester, Jessica A, additional, Sanmiguel, Julio, additional, Estelien, Reynette, additional, Michalson, Kristofer T, additional, Diop, Cheikh, additional, Maciorowski, Dawid, additional, Qi, Wenbin, additional, Hudspeth, Elissa, additional, Cucalon, Allison, additional, Dyer, Cecilia D, additional, Pampena, M. Betina, additional, Knox, James J., additional, LaRocque, Regina C, additional, Charles, Richelle C, additional, Li, Dan, additional, Kim, Maya, additional, Sheridan, Abigail, additional, Storm, Nadia, additional, Johnson, Rebecca I, additional, Feldman, Jared, additional, Hauser, Blake M, additional, Zinn, Eric, additional, Ryan, Aisling, additional, Kobayashi, Dione T, additional, Chauhan, Ruchi, additional, McGlynn, Marion, additional, Ryan, Edward T, additional, Schmidt, Aaron G, additional, Price, Brian, additional, Honko, Anna, additional, Griffiths, Anthony, additional, Yaghmour, Sam, additional, Hodge, Robert, additional, Betts, Michael R., additional, Freeman, Mason W, additional, Wilson, James M, additional, and Vandenberghe, Luk H, additional

Published
2021
Full Text
View/download PDF

13. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro

Author

Xiao, Tianshu, primary, Lu, Jianming, additional, Zhang, Jun, additional, Johnson, Rebecca I., additional, McKay, Lindsay G.A., additional, Storm, Nadia, additional, Lavine, Christy L., additional, Peng, Hanqin, additional, Cai, Yongfei, additional, Rits-Volloch, Sophia, additional, Lu, Shen, additional, Quinlan, Brian D., additional, Farzan, Michael, additional, Seaman, Michael S., additional, Griffiths, Anthony, additional, and Chen, Bing, additional

Published
2020
Full Text
View/download PDF

17. Alston Virus, a Novel Paramyxovirus Isolated from Bats Causes Upper Respiratory Tract Infection in Experimentally Challenged Ferrets.

Author

Johnson, Rebecca I., Tachedjian, Mary, Rowe, Brenton, Clayton, Bronwyn A., Layton, Rachel, Bergfeld, Jemma, Wang, Lin-Fa, and Marsh, Glenn A.

Subjects
*PARAMYXOVIRUSES, *PTEROPODIDAE, *RESPIRATORY infections, *ZOONOSES, *NUCLEOTIDE sequencing
Abstract

Multiple viruses with zoonotic potential have been isolated from bats globally. Here we describe the isolation and characterization of a novel paramyxovirus, Alston virus (AlsPV), isolated from urine collected from an Australian pteropid bat colony in Alstonville, New South Wales. Characterization of AlsPV by whole-genome sequencing and analyzing antigenic relatedness revealed it is a rubulavirus that is closely related to parainfluenza virus 5 (PIV5). Intranasal exposure of mice to AlsPV resulted in no clinical signs of disease, although viral RNA was detected in the olfactory bulbs of two mice at 21 days post exposure. Oronasal challenge of ferrets resulted in subclinical upper respiratory tract infection, viral shedding in respiratory secretions, and detection of viral antigen in the olfactory bulb of the brain. These results imply that AlsPV may be similar to PIV5 in its ability to infect multiple mammalian host species. This isolation of a novel paramyxovirus with the potential to transmit from bats to other mammalian species reinforces the importance of continued surveillance of bats as a source of emerging viruses. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

18. Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates.

Author

Zabaleta N, Dai W, Bhatt U, Chichester JA, Sanmiguel J, Estelien R, Michalson KT, Diop C, Maciorowski D, Qi W, Hudspeth E, Cucalon A, Dyer CD, Pampena MB, Knox JJ, LaRocque RC, Charles RC, Li D, Kim M, Sheridan A, Storm N, Johnson RI, Feldman J, Hauser BM, Zinn E, Ryan A, Kobayashi DT, Chauhan R, McGlynn M, Ryan ET, Schmidt AG, Price B, Honko A, Griffiths A, Yaghmour S, Hodge R, Betts MR, Freeman MW, Wilson JM, and Vandenberghe LH

Abstract

The SARS-CoV-2 pandemic has affected more than 70 million people worldwide and resulted in over 1.5 million deaths. A broad deployment of effective immunization campaigns to achieve population immunity at global scale will depend on the biological and logistical attributes of the vaccine. Here, two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and nonhuman primates following a single injection. Peak neutralizing antibody titers remain sustained at 5 months and are complemented by functional memory T-cells responses. The AAVrh32.33 capsid of the AAVCOVID vaccine is an engineered AAV to which no relevant pre-existing immunity exists in humans. Moreover, the vaccine is stable at room temperature for at least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry. Thus, this methodology holds as a very promising single dose, thermostable vaccine platform well-suited to address emerging pathogens on a global scale.

Published
2021
Full Text
View/download PDF

19. Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.

Author

Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Griffiths A, and Abraham J

Abstract

The SARS-CoV-2 viral spike (S) protein mediates attachment and entry into host cells and is a major target of vaccine and drug design. Potent SARS-CoV-2 neutralizing antibodies derived from closely related antibody heavy chain genes (IGHV3-53 or 3-66) have been isolated from multiple COVID-19 convalescent individuals. These usually contain minimal somatic mutations and bind the S receptor-binding domain (RBD) to interfere with attachment to the cellular receptor angiotensin-converting enzyme 2 (ACE2). We used antigen-specific single B cell sorting to isolate S-reactive monoclonal antibodies from the blood of a COVID-19 convalescent individual. The seven most potent neutralizing antibodies were somatic variants of the same IGHV3-53-derived antibody and bind the RBD with varying affinity. We report X-ray crystal structures of four Fab variants bound to the RBD and use the structures to explain the basis for changes in RBD affinity. We show that a germline revertant antibody binds tightly to the SARS-CoV-2 RBD and neutralizes virus, and that gains in affinity for the RBD do not necessarily correlate with increased neutralization potency, suggesting that somatic mutation is not required to exert robust antiviral effect. Our studies clarify the molecular basis for a heavily germline-biased human antibody response to SARS-CoV-2.

Published
2020
Full Text
View/download PDF

20. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.

Author

Xiao T, Lu J, Zhang J, Johnson RI, McKay LGA, Storm N, Lavine CL, Peng H, Cai Y, Rits-Volloch S, Lu S, Quinlan BD, Farzan M, Seaman MS, Griffiths A, and Chen B

Abstract

Effective intervention strategies are urgently needed to control the COVID-19 pandemic. Human angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase that forms a dimer and serves as the cellular receptor for SARS-CoV-2. It is also a key negative regulator of the renin-angiotensin system (RAS), conserved in mammals, which modulates vascular functions. We report here the properties of a trimeric ACE2 variant, created by a structure-based approach, with binding affinity of ~60 pM for the spike (S) protein of SARS-CoV-2, while preserving the wildtype peptidase activity as well as the ability to block activation of angiotensin II receptor type 1 in the RAS. Moreover, the engineered ACE2 potently inhibits infection of SARS-CoV-2 in cell culture. These results suggest that engineered, trimeric ACE2 may be a promising anti-SARS-CoV-2 agent for treating COVID-19.

Published
2020
Full Text
View/download PDF

21. Rotavirus NSP6 localizes to mitochondria via a predicted N-terminal a-helix.

Author

Holloway G, Johnson RI, Kang Y, Dang VT, Stojanovski D, and Coulson BS

Subjects
Animals, Cell Line, Gene Expression Regulation, Viral physiology, HEK293 Cells, Humans, Protein Transport, Rotavirus genetics, Virus Replication, Mitochondria physiology, Rotavirus metabolism, Viral Nonstructural Proteins physiology
Abstract

Specific roles have been ascribed to each of the 12 known rotavirus proteins apart from the non-structural protein 6 (NSP6). However, NSP6 may be present at sites of viral replication within the cytoplasm. Here we report that NSP6 from diverse species of rotavirus A localizes to mitochondria via conserved sequences in a predicted N-terminal a-helix. This suggests that NSP6 may affect mitochondrial functions during rotavirus infection.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results